This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Reckitt Benckiser Prepares for Pharma Unit Spinoff

LONDON (The Deal) -- British consumer healthcare and cleaning products company Reckitt Benckiser said on Monday it has decided to spin off its pharmaceuticals unit on the London Stock Exchange within the next 12 months after the division's core Suboxone heroin-withdrawal aid lost U.S. patent protection.

Reckitt, of Slough, England, made the announcement as it released first-half results that showed that pharmaceuticals sales fell 14% to 344 million pounds, while the division's operating profit slipped 20% to 183 million pounds. The Slough, England company, whose group first-half revenue was just under 4.7 billion pounds, put the business up for review in October.

Reckitt CEO Rakesh Kapoor told investors on Monday that the company had decided the pharmaceuticals unit will fare better "under a board that is focused on specialty pharmaceuticals and not on consumer healthcare that wakes up every morning thinking: how can we create value?"

"We are not ruling out selling this business," he said. "The preparations for a separation are to a large extent common whatever the form of the separation but we believe that a demerger is likely to be the route that adds most value."

"We do believe a standalone RBP will be a magnet for interesting business development opportunities," including licensing deals, he added.

The company began the pharma review after the Food and Drug Administration approved two generic alternatives to Suboxone. Reckitt then discontinued its Suboxone tablets and switched to a cheaper, sublingual version of the drug, which it said is proving resilient.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $127.60 2.28%
FB $83.09 2.87%
GOOG $535.38 2.16%
TSLA $205.27 -0.74%
YHOO $44.66 0.46%

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs